- Datum15.01.2025
- Uhrzeit15:00 - 15:30 Uhr
- Veranstalter
stock3
Thomas May
Moderator
Astrazeneca PLC Aktie
Verkaufen
Kaufen
Astrazeneca PLC Chart
stock3 TerminalDu willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnen
Astrazeneca PLC Realtime-Kurs
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (XETRA)
1,41 %
Intraday
0,24 %
1 Woche
0,24 %
1 Monat
3,44 %
Seit Jahresbeginn
4,51 %
1 Jahr
23,82 %
3 Jahre
39,87 %
5 Jahre
120,80 %
10 Jahre
Wikifolio
Passender Service zu Astrazeneca PLC
Webinar zu Astrazeneca PLC
Kursinformationen (XETRA)
- Tagestief / Hoch (€)-
- 52W-Tief / Hoch (€)112,350-158,200
- Jahrestief / Hoch (€)112,350-158,200
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Astrazeneca PLC
| Ex-Datum | Fiskaljahr | Dividende | Rendite |
|---|---|---|---|
| - | 2027 (e) | ||
| - | 2026 (e) | ||
| - | 2025 (e) | ||
| - | 2024 (e) | ||
| 08.08.2024 | 2024 | 0,776 £ | 0,61 % |
| 22.02.2024 | 2023 | 1,56 £ | 1,53 % |
| 10.08.2023 | 2023 | 0,718 £ | 0,64 % |
| 23.02.2023 | 2022 | 1,628 £ | 1,43 % |
| 24.02.2022 | 2021 | 1,453 £ | 1,61 % |
| 12.08.2021 | 2021 | 0,648 £ | 0,79 % |
| 11.08.2022 | 2021 | 0,764 £ | 0,70 % |
| 25.02.2021 | 2020 | 1,374 £ | 1,93 % |
| 13.08.2020 | 2020 | 0,696 £ | 0,79 % |
| 27.02.2020 | 2019 | 1,464 £ | 1,97 % |
| 08.08.2019 | 2019 | 0,719 £ | 1,00 % |
| 28.02.2019 | 2018 | 1,468 £ | 2,31 % |
| 09.08.2018 | 2018 | 0,684 £ | 1,13 % |
| 15.02.2018 | 2017 | 1,336 £ | 2,76 % |
| 10.08.2017 | 2017 | 0,689 £ | 1,51 % |
| 11.08.2016 | 2016 | 0,90 $ | 1,33 % |
| 16.02.2017 | 2016 | 1,90 $ | 3,20 % |
| 13.08.2015 | 2015 | 0,575 £ | 1,33 % |
| 18.02.2016 | 2015 | 1,31 £ | 3,03 % |
| 13.08.2014 | 2014 | 0,531 £ | 1,29 % |
| 19.02.2015 | 2014 | 1,25 £ | 2,77 % |
| 14.08.2013 | 2013 | 0,592 £ | 1,78 % |
| 19.02.2014 | 2013 | 1,168 £ | 2,86 % |
| 08.08.2012 | 2012 | 0,581 £ | 1,89 % |
| 13.02.2013 | 2012 | 1,205 £ | 3,98 % |
| 03.08.2011 | 2011 | 0,519 £ | 1,78 % |
| 15.02.2012 | 2011 | 1,236 £ | 4,10 % |
| 02.02.2011 | 2010 | 1,167 £ | 3,76 % |
| 04.08.2010 | 2010 | 0,449 £ | 1,37 % |
| 03.02.2010 | 2010 | 1,054 £ | 3,61 % |
| 05.08.2009 | 2009 | 0,36 £ | 1,27 % |
| 04.02.2009 | 2008 | 1,048 £ | 3,86 % |
| 06.08.2008 | 2008 | 0,278 £ | 1,09 % |
| 06.02.2008 | 2007 | 0,677 £ | 3,24 % |
| 08.08.2007 | 2007 | 0,253 £ | 1,01 % |
| 07.02.2007 | 2006 | 1,23 $ | 2,09 % |
| 09.08.2006 | 2006 | 0,49 $ | - |
| 08.02.2006 | 2005 | 0,92 $ | - |
| 10.08.2005 | 2005 | 0,38 $ | - |
| 11.08.2004 | 2004 | 0,16 £ | - |
| 09.02.2005 | 2004 | 0,343 £ | - |
| 18.02.2004 | 2003 | 0,294 £ | - |
| 20.08.2003 | 2003 | 0,159 £ | - |
| 19.02.2003 | 2002 | 0,285 £ | - |
| 21.08.2002 | 2002 | 0,147 £ | - |
| 22.08.2001 | 2001 | 0,161 £ | - |
| 20.02.2002 | 2001 | 0,332 £ | - |
| 04.09.2000 | 2000 | 0,153 £ | - |
| 21.02.2001 | 2000 | 0,321 £ | - |
| 06.09.1999 | 1999 | 0,23 $ | - |
| 06.03.2000 | 1999 | 0,291 £ | - |
| 14.09.1998 | 1998 | 0,14 £ | - |
| 29.03.1999 | 1998 | 0,28 £ | - |
| 15.09.1997 | 1997 | 0,135 £ | - |
| 16.03.1998 | 1997 | 0,25 £ | - |
| 16.09.1996 | 1996 | 0,125 £ | - |
| 17.03.1997 | 1996 | 0,225 £ | - |
| 18.09.1995 | 1995 | 0,1125 £ | - |
| 18.03.1996 | 1995 | 0,1975 £ | - |
| 13.03.1995 | 1994 | 0,1775 £ | - |
| 12.09.1994 | 1994 | 0,1075 £ | - |
| 14.03.1994 | 1993 | 0,17 £ | - |
| 20.09.1993 | 1993 | 0,105 £ | - |
Termine von Astrazeneca PLC
- Feb6Astrazeneca PLCQ4 2024 Earnings Release
- Apr25Astrazeneca PLCQ1 2025 Earnings Release
- Jul24Astrazeneca PLCQ2 2025 Earnings Release
Beschreibung
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
